1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

AbbVie’s Stalling Tactics On Humira Pay Off – In More Ways Than One

 
• By Michael McCaughan

A US House hearing focused on long-standing criticism of AbbVie for its ability to delay biosimilar competition for Humira. AbbVie was also able to delay the hearing, and that also seemed to work out well for the company.

Richard Gonzalez may expect delays. Photo illustration/Alamy, Getty
Richard Gonzalez may actually enjoy this kind of traffic. • Source: photo illustration/Alamy, Getty

He who hesitates may be lost, but when it comes to testifying about drug pricing, it appears that there is some benefit in putting it off as long as possible.

For AbbVie Inc., at least, it appears to have worked out that way after the company’s CEO, Richard Gonzalez, finally testified as part of the House Oversight Committee’s investigation in drug pricing. His testimony came more than six months after six other industry CEOs shared the spotlight over two days of testimony in front of the committee last fall – and only after the committee voted to authorize a subpoena to compel his appearance

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access

PBMs No Longer Profit From Rebates But Plans Benefit; Should Sponsors Push More For Reform?

 
• By Cathy Kelly

Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.

Why Successful Companies Are ‘Tough On Themselves’ When It Comes To HTA

 
• By Eliza Slawther

Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.